EE81 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia
Value in Health(2023)
Abstract
Immuno-oncology (IO) combination NIVO+IPI and IO+tyrosine kinase inhibitor combination (PEM+AXI) therapies have demonstrated significant clinical benefits over sunitinib in the first-line (1L) treatment of I/P-risk advanced renal cell carcinoma (aRCC). We examined the cost-effectiveness of NIVO+IPI versus PEM+AXI for this from a Colombian payer perspective, utilizing a novel approach to estimate comparative efficacy between the treatments.
MoreTranslated text
Key words
nivolumab plus ipilimumab,versus pembrolizumab,renal cell carcinoma,axitinib,cost-effectiveness,first-line
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined